National Institutes of Health

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Boston University Chobanian & Avedisian School of Medicine is a school of medicine focus on treating disadvantaged and underserved populations.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.

Applied BioMath, LLC, established in 2013 and headquartered in Concord, Massachusetts, specializes in systems biology and pharmacology services aimed at accelerating drug research and development for biotechnology and pharmaceutical companies. The company employs advanced mathematical modeling and simulation techniques to provide predictive guidance and insights throughout the drug discovery process. Its offerings include pathway model development, target and biomarker discovery, and feasibility assessments for various drug targets. Additionally, Applied BioMath conducts analyses of competitor compounds and projects drug properties and dosing for clinical phases. The firm utilizes proprietary algorithms and high-performance computational biology to optimize decision-making and mitigate risks associated with late-stage attrition in drug development. With additional offices in Cambridge and Oakland, Applied BioMath collaborates strategically with industry leaders such as Sanofi and Xilio Therapeutics to enhance its service offerings.

MaineHealth is a not-for-profit family of leading high-quality providers and other healthcare organizations working together so our communities are the healthiest in America. Ranked among the nation's top 100 integrated healthcare delivery networks, MaineHealth member organizations include Maine Medical Center, Franklin Community Health Network, LincolnHealth, Maine Behavioral Healthcare,

Barrett Technology, LLC, established in 1990 and located in Newton, Massachusetts, specializes in the design and manufacture of advanced robotic manipulators. The company has pioneered technology that enhances flexibility in articulated arms and hands, positioning itself as a leader in this field. Renowned for its innovative solutions, Barrett Technology earned recognition in the Guinness Book of World Records for its advanced manipulator technology. The company offers a high degree of versatility, catering to a wide range of applications across various industries.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery platforms and the development of quality-of-life medicines. The company focuses on enhancing drug discovery and manufacturing through its innovative biotechnology and nanotechnology solutions. Aphios offers a range of therapeutic products aimed at health maintenance, disease prevention, and the treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-based product, and various formulations of Taxotere for cancer treatment, which aim to improve oral bioavailability and target specific cancer cells. In addition to its therapeutic offerings, Aphios develops advanced technologies such as SuperFluids for pharmaceutical manufacturing and virology testing services, contributing to the safety and efficacy of drug therapies. Founded in 1993, Aphios continues to push the boundaries of medical science with its focus on innovative solutions for complex health challenges.

Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Worcester Polytechnic Institute (WPI), located in Worcester, Massachusetts, is a prestigious technological university founded in 1865. Renowned for its commitment to project-based learning, WPI emphasizes practical application of theoretical knowledge to address real-world challenges. The university boasts a distinguished faculty and state-of-the-art research facilities, fostering an environment rich in innovation and collaboration. WPI attracts ambitious students eager to engage in hands-on experiences that prepare them to make meaningful contributions to society. With a strong focus on developing skills that are crucial in today’s dynamic landscape, WPI positions itself as a leader in education and research, dedicated to empowering its students and faculty to achieve excellence.

Babson College is an independent, not-for-profit institution renowned for its focus on entrepreneurship education. It is accredited by prestigious organizations including the Association to Advance Collegiate Schools of Business and the European Quality Improvement System. The college offers a comprehensive undergraduate program that integrates business and liberal arts, alongside the F.W. Olin Graduate School of Business, which provides highly regarded MBA and MS degrees. Babson also features an Executive Education program tailored for professionals seeking to enhance their skills in a dynamic business landscape. The faculty is distinguished, with a significant majority holding doctoral degrees and possessing extensive real-world experience in various fields. Babson engages in global research initiatives that serve as benchmarks for numerous authorities worldwide, and operates Babson Global, which collaborates with diverse partners to promote entrepreneurship education. Additionally, the Summer Venture Program supports aspiring entrepreneurs through an intensive 10-week experience that includes mentorship, resources, and networking opportunities, culminating in a showcase event that connects participants with the broader startup community.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company that develops and commercializes a proprietary wearable microfluidic sensing platform designed for athletes. Founded in 2017, the company focuses on analyzing small droplets of sweat directly from the skin to measure a range of health and performance metrics. Its technology allows for non-invasive monitoring of sweat biomarkers, skin health, and physiological states in real-time, facilitating personalized management of hydration, nutrition, and overall health. Epicore's innovative platform is grounded in extensive research in microfluidics and soft materials, aiming to enhance athletic performance and health management through accessible and cost-effective solutions.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Helixbind is a biotechnology company based in Worcester, Massachusetts. Founded in 2012, it specializes in developing a pathogen identification platform designed to rapidly detect and identify bloodstream infections directly from whole blood specimens, enabling timely targeted antimicrobial interventions.

CaroGen Corporation is a biopharmaceutical company developing recombinant virus-like vesicles for vaccines against infectious diseases. Its platform technology enables the creation of vaccines targeting hepatitis B, C, influenza, and other viral agents.

The University of Vermont (UVM) is a public research university established in 1791, making it one of the oldest universities in the United States. Located in Burlington, Vermont, UVM offers a wide range of academic programs through its various schools and colleges, including business, social sciences, science, and medicine. Notable features of the campus include the historic University Green, the Dudley H. Davis Center, which is recognized for its environmental sustainability, the Fleming Museum of Art, and the Gutterson/Patrick athletic complex. The university's College of Medicine is affiliated with Fletcher Allen Health Care, the largest hospital complex in Vermont. UVM's extensive academic offerings and affiliations contribute to its role as a significant educational institution in the region.

The University of Massachusetts Amherst is a public research and land-grant university that offers undergraduate, master's, and doctoral programs. It serves as the flagship campus of the University of Massachusetts system. The university has multiple academic departments and research facilities that support a range of disciplines.

Helixbind is a biotechnology company based in Worcester, Massachusetts. Founded in 2012, it specializes in developing a pathogen identification platform designed to rapidly detect and identify bloodstream infections directly from whole blood specimens, enabling timely targeted antimicrobial interventions.

Founded in 2011, WindGap Medical specializes in the development and manufacturing of compact epinephrine autoinjectors for treating anaphylaxis. Headquartered in Watertown, Massachusetts.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company focuses on developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its proprietary HEALER technology platform, Thetis Pharmaceuticals creates novel small molecule drugs that leverage the pharmacological properties of lipids to promote tissue regeneration and manage inflammation effectively. The company's research has yielded resolvins, which are potent agonists designed to facilitate inflammation resolution and tissue repair. These therapies aim to help healthcare professionals regulate the body's inflammatory response without compromising immune function, addressing the challenges associated with overactive inflammation in various diseases.

Founded in 2015, Skelmet specializes in designing and producing custom-fit head-worn products. Utilizing advanced 3D scanning and printing technologies, the company offers bespoke sunglasses tailored to individual facial measurements, ensuring optimal fit and performance for various sports activities.

CaroGen Corporation is a biopharmaceutical company developing recombinant virus-like vesicles for vaccines against infectious diseases. Its platform technology enables the creation of vaccines targeting hepatitis B, C, influenza, and other viral agents.

Rhode Island Hospital operates as a hospital in Rhode Island. It offers cancer care, cardiac care, clinical coordinating, colorectal care, dental care, diabetes and endocrinology, diagnostic imaging (radiology), education, emergency medicine, medical simulation, mental health, neurosciences, nursing, oncology, orthopedics, pain management, rehabilitation, social work, stroke, surgery, trauma care, and transplantation services. The company also provides breast imaging, pediatric, cardiovascular surgery programs, electrophysiology, endoscopy, and sleep disorder services; and treatment for mood disorders, such as major depression, chronic major depression, and bipolar disorders. In addition, it offers treatment for tumors and vascular malformations in the brain; and mental health services for problem gamblers. Rhode Island Hospital was founded in 1863 and is based in Providence, Rhode Island.

The University of Massachusetts Medical School (UMMS), founded in 1962 and located in Worcester, Massachusetts, is dedicated to providing affordable, high-quality medical education with a focus on increasing the number of primary care physicians in underserved areas. The institution aims to advance health and wellness in diverse communities both locally and globally through its commitment to education, research, healthcare delivery, and public service. Consistently recognized as a leading medical school for primary care education, UMMS plays a vital role in shaping healthcare professionals and addressing public health challenges.

The University of Vermont (UVM) is a public research university established in 1791, making it one of the oldest universities in the United States. Located in Burlington, Vermont, UVM offers a wide range of academic programs through its various schools and colleges, including business, social sciences, science, and medicine. Notable features of the campus include the historic University Green, the Dudley H. Davis Center, which is recognized for its environmental sustainability, the Fleming Museum of Art, and the Gutterson/Patrick athletic complex. The university's College of Medicine is affiliated with Fletcher Allen Health Care, the largest hospital complex in Vermont. UVM's extensive academic offerings and affiliations contribute to its role as a significant educational institution in the region.

If you reside in the Kingston, Rhode Island area and are looking for an undergraduate or graduate program for academic study, why not check out the University of Rhode Island? Programs available to choose from as a major include the interesting Animal and Veterinary Science, Business Administration, Civil and Environmental Engineering, Geology and Geological Oceanography, Human Development and Family Studies, International Engineering, Journalism, and Nursing, among many others. URI has a festive student life which includes both entertainment events and organizations which can help students get a leg up in the career search. Study abroad programs are offered during the summer and school year. There is also a strong Greek life, Student Senate, dining, and athletic programs. Other services include a counseling center and health services. If you qualify for financial aid like the Centennial and University Scholarships, your entire tuition may be covered. There are also grants and loans that can help cover tuition and other educational expenses. When it comes time to search for a job, the career service center can help students with writing resumes, interview preparation, meeting potential employers, and much more.

Aquinnah Pharmaceuticals, Inc., founded in 2014 and based in Cambridge, Massachusetts, is a pharmaceutical company dedicated to developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company focuses on innovative research aimed at modulating neurodegenerative stress granules, which are thought to play a significant role in the pathology of ALS. Through its specialized approach, Aquinnah Pharmaceuticals aims to address critical unmet medical needs in the field of neurodegeneration.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company focuses on developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its proprietary HEALER technology platform, Thetis Pharmaceuticals creates novel small molecule drugs that leverage the pharmacological properties of lipids to promote tissue regeneration and manage inflammation effectively. The company's research has yielded resolvins, which are potent agonists designed to facilitate inflammation resolution and tissue repair. These therapies aim to help healthcare professionals regulate the body's inflammatory response without compromising immune function, addressing the challenges associated with overactive inflammation in various diseases.

Vaxess Technologies is a biotechnology company focused on silk biomaterial platforms for vaccine and therapeutic delivery. It develops the MIMIX microneedle patch for transdermal, sustained-release delivery of vaccines and therapies, designed to improve stability and ease of use, including formulations that do not require cold chain storage. The MATRIX formulation and drying platform supports thermostable vaccine, therapeutic, and diagnostic products. The company aims to enable long-term immune responses and easier distribution, including in low-resource settings. Its technology supports oncology and infectious disease applications, including therapies that promote durable anti-tumor immunity and improved treatment outcomes. Founded in 2011 and based in Boston, the company positions its platforms to enable stable, targeted delivery and potentially reduce treatment burden for patients.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company focuses on developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its proprietary HEALER technology platform, Thetis Pharmaceuticals creates novel small molecule drugs that leverage the pharmacological properties of lipids to promote tissue regeneration and manage inflammation effectively. The company's research has yielded resolvins, which are potent agonists designed to facilitate inflammation resolution and tissue repair. These therapies aim to help healthcare professionals regulate the body's inflammatory response without compromising immune function, addressing the challenges associated with overactive inflammation in various diseases.

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Novo Biosciences, Inc. is a biotechnology company founded in 2013 and based in Bar Harbor, Maine. The company specializes in the development of small molecule therapies aimed at reversing the damage caused by heart attacks. Its innovative drugs activate dormant genetic mechanisms that promote self-repair and tissue regeneration, allowing both humans and animals to heal more effectively. By harnessing these natural processes, Novo Biosciences seeks to improve health outcomes for patients suffering from life-threatening cardiac conditions.

Mobile Sense Technologies, Inc. specializes in the development of innovative wearable wireless sensor bands for cardiac monitoring. Its primary product, SensBand, is designed to be worn on the arm or wrist and enables automatic monitoring, detection, and reporting of dangerous heart arrhythmias directly to patients and their healthcare providers. Founded in 2016 and based in Farmington, Connecticut, the company has invested significant resources into creating a platform for differentiated wearables. The technology includes non-adhesive, wireless, and waterproof sensors that provide continuous ECG and PPG recordings, allowing for 24/7 monitoring and classification of heart conditions. Mobile Sense Technologies aims to transform the traditional diagnostic market by utilizing advanced wearables that facilitate long-term management of cardiac health.

Maine Medical Center is a 637 licensed-bed teaching hospital located at 22 Bramhall Street in Portland, Maine

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Helixbind is a biotechnology company based in Worcester, Massachusetts. Founded in 2012, it specializes in developing a pathogen identification platform designed to rapidly detect and identify bloodstream infections directly from whole blood specimens, enabling timely targeted antimicrobial interventions.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

Founded in 2014, Aldatu Biosciences specializes in adaptive PCR diagnostics for global health. Its proprietary PANDAA technology enables detection of highly variable genomic regions, empowering healthcare providers to improve patient outcomes and reduce costs, particularly in HIV care.

EpiVax, Inc. is a biotechnology company specializing in computational immunology tools. Established in 1998 and based in Providence, Rhode Island, EpiVax focuses on developing innovative solutions to assess and mitigate immunogenic risks associated with protein therapeutics. The company offers a range of services, including interactive protein screening, immunogenicity predictions for antibody candidates, and informatics tools for evaluating host cell protein contaminants. Additionally, EpiVax provides deimmunization services to reduce immunogenicity in therapeutic proteins and develops epitope-based vaccines targeting diseases such as smallpox, tularemia, tuberculosis, and influenza. Its advanced platform also facilitates the design of epitope-driven vaccines and includes capabilities for lab-based immunogenicity assays and T cell assays. Through its comprehensive analytical capabilities, EpiVax aims to enhance the development of immunotherapeutics while minimizing side effects for patients.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).

Helixbind is a biotechnology company based in Worcester, Massachusetts. Founded in 2012, it specializes in developing a pathogen identification platform designed to rapidly detect and identify bloodstream infections directly from whole blood specimens, enabling timely targeted antimicrobial interventions.

Embera NeuroTherapeutics, Inc. is a pharmaceutical company based in Sudbury, Massachusetts, founded in 2005. The company is focused on developing innovative treatments for smoking cessation, cocaine dependence, and other addictions, an area where effective drug therapies are limited or nonexistent. Embera's flagship product, EMB-001, combines the benzodiazepine oxazepam with metyrapone, a cortisol synthesis inhibitor, to target the stress response system and specific brain functions linked to cravings and relapse. This dual-action approach aims to modulate various stress-related pathways, thereby reducing the cravings that drive addictive behaviors. By addressing the underlying mechanisms of addiction, Embera NeuroTherapeutics seeks to offer a more effective solution for individuals struggling with these disorders.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Sober Grid, Inc. is a digital health company that operates a sober social network aimed at supporting individuals in recovery from substance use disorders. Incorporated in 2015 and based in Boston, Massachusetts, the company has developed a mobile application available on both iOS and Android platforms. The app allows users to connect with others who are also navigating sobriety, fostering a community where they can share experiences and challenges. Sober Grid's platform is utilized in over 170 countries and has been accessed more than 20 million times. It integrates features such as GPS locator interfaces, direct messaging, and educational resources, while also offering certified coaching services available 24/7. The app employs a unique community-based approach to chronic disease management, utilizing predictive analytics to anticipate relapse risks and provide timely interventions. Sober Grid's commitment to improving health outcomes is supported by research collaborations with esteemed institutions like Harvard Medical School and the University of Pennsylvania, demonstrating its effectiveness in reducing relapse rates among users.

Founded in 1764, Brown University is an independent, coeducational Ivy League institution located in Providence, Rhode Island. It offers undergraduate and graduate programs across various disciplines, including the Alpert Medical School, School of Public Health, School of Engineering, and School of Professional Studies. Known for its commitment to exceptional undergraduate instruction and research, Brown has a diverse student body of approximately 6,200 undergraduates and 2,000 graduate students.

TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company employs its proprietary TetraExpress system to produce recombinant human ion channel proteins, which are essential for creating complex therapeutic agents. Among its offerings is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. TetraGenetics specializes in producing difficult-to-express eukaryotic membrane and secretory proteins, including vaccine antigens and monoclonal antibodies, which are crucial for treating various human and animal diseases. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., further enhancing its capabilities in therapeutic innovation.

Aquinnah Pharmaceuticals, Inc., founded in 2014 and based in Cambridge, Massachusetts, is a pharmaceutical company dedicated to developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company focuses on innovative research aimed at modulating neurodegenerative stress granules, which are thought to play a significant role in the pathology of ALS. Through its specialized approach, Aquinnah Pharmaceuticals aims to address critical unmet medical needs in the field of neurodegeneration.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries, concussions, acute ischemic strokes, and neurodegenerative disorders like Alzheimer’s disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selective astrocyte activation. Its lead product, AST-004, is a novel small molecule designed for acute administration that protects and repairs damaged neurons by selectively stimulating astrocytes. Astrocyte Pharmaceuticals aims to advance innovative therapeutic agents to improve recovery and well-being for patients suffering from brain injuries.

Helixbind is a biotechnology company based in Worcester, Massachusetts. Founded in 2012, it specializes in developing a pathogen identification platform designed to rapidly detect and identify bloodstream infections directly from whole blood specimens, enabling timely targeted antimicrobial interventions.

The Vermont Genetics Network (VGN) is funded by a five-year, $16.5 million award from the National Center for Research Resources (NCRR), and is part of a National Institutes of Health (NIH) initiative called IDeA Networks of Biomedical Research Excellence (INBRE). Under the direction of Dr. Judith Van Houten, the VGN, which links scientists at Castleton State College, Johnson State College, Middlebury College, Norwich University and St. Michael's College to resources at UVM, is designed to provide funding for research, equipment and technology necessary to enhance competitiveness for national funding for genetics research. Other aims of the project include increasing the number of undergraduates who go on to biomedical careers from the baccalaureate colleges, to provide and support bioinformatics capability in the state, and to increase the diversity of biomedical scientists.

Founded in 2014, Aldatu Biosciences specializes in adaptive PCR diagnostics for global health. Its proprietary PANDAA technology enables detection of highly variable genomic regions, empowering healthcare providers to improve patient outcomes and reduce costs, particularly in HIV care.

Vaxess Technologies is a biotechnology company focused on silk biomaterial platforms for vaccine and therapeutic delivery. It develops the MIMIX microneedle patch for transdermal, sustained-release delivery of vaccines and therapies, designed to improve stability and ease of use, including formulations that do not require cold chain storage. The MATRIX formulation and drying platform supports thermostable vaccine, therapeutic, and diagnostic products. The company aims to enable long-term immune responses and easier distribution, including in low-resource settings. Its technology supports oncology and infectious disease applications, including therapies that promote durable anti-tumor immunity and improved treatment outcomes. Founded in 2011 and based in Boston, the company positions its platforms to enable stable, targeted delivery and potentially reduce treatment burden for patients.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, focused on developing portable point-of-care diagnostic platforms to enhance disease management globally. Founded in 2008, the company offers several innovative products, including Daktari Virology for the detection of Hepatitis C and HIV, Daktari InSight, a cloud-based data management service, and Daktari Sickle Cell, which identifies infants with sickle cell disease from a single drop of blood. Daktari’s technology is designed specifically for resource-poor markets, featuring built-in wireless connectivity that facilitates real-time data sharing among healthcare providers. By delivering critical diagnostic information efficiently, Daktari aims to improve clinical outcomes and support global health initiatives. The company's commitment to affordability and quality ensures that its products are accessible to healthcare professionals and patients worldwide.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

Vaxess Technologies is a biotechnology company focused on silk biomaterial platforms for vaccine and therapeutic delivery. It develops the MIMIX microneedle patch for transdermal, sustained-release delivery of vaccines and therapies, designed to improve stability and ease of use, including formulations that do not require cold chain storage. The MATRIX formulation and drying platform supports thermostable vaccine, therapeutic, and diagnostic products. The company aims to enable long-term immune responses and easier distribution, including in low-resource settings. Its technology supports oncology and infectious disease applications, including therapies that promote durable anti-tumor immunity and improved treatment outcomes. Founded in 2011 and based in Boston, the company positions its platforms to enable stable, targeted delivery and potentially reduce treatment burden for patients.

Boston Medical Center is a private, not-for-profit, academic medical center that provides its patients with trauma and emergency services. It is dedicated to providing accessible health care services to everyone. It also offers many outreach programs and services such as health screenings, smoking cessation, prevention food pantry, bWell center, and interpreter services. Boston Medical Center is based in Boston, Massachusetts.

The Miriam Hospital is a private, not-for-profit hospital at 164 Summit Avenue in Providence, in the U.S. state of Rhode Island. It is a major teaching affiliate of the Warren Alpert Medical School of Brown University.

Founded in 2007, Artaic specializes in designing and fabricating custom tile work for commercial and residential markets. Utilizing computer-aided design software and robotic assembly systems, the company creates innovative mosaics for various industries such as hospitality, retail, and public art.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, focused on developing portable point-of-care diagnostic platforms to enhance disease management globally. Founded in 2008, the company offers several innovative products, including Daktari Virology for the detection of Hepatitis C and HIV, Daktari InSight, a cloud-based data management service, and Daktari Sickle Cell, which identifies infants with sickle cell disease from a single drop of blood. Daktari’s technology is designed specifically for resource-poor markets, featuring built-in wireless connectivity that facilitates real-time data sharing among healthcare providers. By delivering critical diagnostic information efficiently, Daktari aims to improve clinical outcomes and support global health initiatives. The company's commitment to affordability and quality ensures that its products are accessible to healthcare professionals and patients worldwide.

Founded in 2007, Artaic specializes in designing and fabricating custom tile work for commercial and residential markets. Utilizing computer-aided design software and robotic assembly systems, the company creates innovative mosaics for various industries such as hospitality, retail, and public art.

Founded in 2007, Artaic specializes in designing and fabricating custom tile work for commercial and residential markets. Utilizing computer-aided design software and robotic assembly systems, the company creates innovative mosaics for various industries such as hospitality, retail, and public art.

Founded in 2007, Artaic specializes in designing and fabricating custom tile work for commercial and residential markets. Utilizing computer-aided design software and robotic assembly systems, the company creates innovative mosaics for various industries such as hospitality, retail, and public art.

Immunetics, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development and marketing of immunoassay and molecular probe technology solutions for diagnosing infectious diseases. Founded in 1987, the company offers a diverse range of diagnostic assays, including the C6 B.burgdorferi (Lyme) ELISA Kit for detecting Lyme disease antibodies, the QuickELISA Anthrax-PA Kit for identifying anthrax antibodies, and the BacTx Test for assessing bacterial contamination in platelets. Immunetics also produces instruments such as the Miniblotter system for various assay formats and cell adhesion flow chambers for studying cell interactions. With a commitment to addressing emerging health risks, the company is actively working on new diagnostic tests for diseases like Babesiosis and Chagas disease. Immunetics distributes its products globally, serving healthcare professionals across multiple countries.

Galenea Corp. is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing therapeutics for central nervous system (CNS) diseases. Founded in 2003, the company specializes in treating psychiatric disorders, including schizophrenia, and obesity, focusing on innovative therapeutic approaches involving 5-HT2C agonists and calcineurin modulation. Galenea employs advanced technologies for in vitro and in vivo synaptic functional screening, as well as brain slice electrophysiology assays, to record disease-relevant neuronal activity in the prefrontal cortex. These methodologies allow for the evaluation of drug candidates in animal models performing tasks related to memory and cognition, ultimately enabling better predictions of human responses to treatments.

EpiVax, Inc. is a biotechnology company specializing in computational immunology tools. Established in 1998 and based in Providence, Rhode Island, EpiVax focuses on developing innovative solutions to assess and mitigate immunogenic risks associated with protein therapeutics. The company offers a range of services, including interactive protein screening, immunogenicity predictions for antibody candidates, and informatics tools for evaluating host cell protein contaminants. Additionally, EpiVax provides deimmunization services to reduce immunogenicity in therapeutic proteins and develops epitope-based vaccines targeting diseases such as smallpox, tularemia, tuberculosis, and influenza. Its advanced platform also facilitates the design of epitope-driven vaccines and includes capabilities for lab-based immunogenicity assays and T cell assays. Through its comprehensive analytical capabilities, EpiVax aims to enhance the development of immunotherapeutics while minimizing side effects for patients.

ProThera Biologics, Inc., established in 2001 and headquartered in Providence, Rhode Island, develops human plasma proteins for controlling inflammation through modulating multiple pathways. The company focuses on creating diagnostic and therapeutic products based on natural serine protease inhibitors, with a primary focus on inter-alpha inhibitor proteins for treating inflammatory diseases like sepsis and cancer. ProThera Biologics has a strategic partnership with ProMetic Life Sciences Inc. The company was founded by Yow-Pin Lim, MD/PhD, and Douglas C. Hixson, PhD, both actively engaged in biomedical research at the Carcinogenesis Laboratory of Rhode Island Hospital.

The University of New England is a health sciences university located in Biddeford, Maine, distinguished by its commitment to liberal arts education and innovative health programs. It hosts internationally recognized scholars and offers over 40 undergraduate, graduate, and professional degree programs, including Maine's only medical school. The university operates two campuses in Biddeford and Portland, providing interprofessional education through its various colleges, such as the College of Osteopathic Medicine and the College of Pharmacy. The institution actively manages an endowment fund, which invests donations to generate a reliable income source that supports its strategic initiatives and enhances educational opportunities for its students. The fund's assets are overseen by the university's executive management team, ensuring effective governance and alignment with the university's mission.

EpiVax, Inc. is a biotechnology company specializing in computational immunology tools. Established in 1998 and based in Providence, Rhode Island, EpiVax focuses on developing innovative solutions to assess and mitigate immunogenic risks associated with protein therapeutics. The company offers a range of services, including interactive protein screening, immunogenicity predictions for antibody candidates, and informatics tools for evaluating host cell protein contaminants. Additionally, EpiVax provides deimmunization services to reduce immunogenicity in therapeutic proteins and develops epitope-based vaccines targeting diseases such as smallpox, tularemia, tuberculosis, and influenza. Its advanced platform also facilitates the design of epitope-driven vaccines and includes capabilities for lab-based immunogenicity assays and T cell assays. Through its comprehensive analytical capabilities, EpiVax aims to enhance the development of immunotherapeutics while minimizing side effects for patients.

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company based in Hopkinton, Massachusetts, focused on the discovery and development of therapeutics for various cancers and inflammatory diseases. Utilizing its proprietary small molecule nucleotide platform, the company is advancing a pipeline of innovative products, including SB 11285, a next-generation immunotherapeutic designed for the treatment of selected cancers, and novel STING antagonist compounds aimed at addressing autoimmune and inflammatory diseases. Spring Bank is also developing a platform to facilitate the targeted delivery of therapeutic payloads. The company's collaboration with Roche involves exploring the co-administration of SB 11285. Established in 2002 and formerly known as Spring Bank Technologies, Inc., the company rebranded to Spring Bank Pharmaceuticals in 2008, reflecting its commitment to addressing significant healthcare challenges through its unique drug discovery technology.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

EpiVax, Inc. is a biotechnology company specializing in computational immunology tools. Established in 1998 and based in Providence, Rhode Island, EpiVax focuses on developing innovative solutions to assess and mitigate immunogenic risks associated with protein therapeutics. The company offers a range of services, including interactive protein screening, immunogenicity predictions for antibody candidates, and informatics tools for evaluating host cell protein contaminants. Additionally, EpiVax provides deimmunization services to reduce immunogenicity in therapeutic proteins and develops epitope-based vaccines targeting diseases such as smallpox, tularemia, tuberculosis, and influenza. Its advanced platform also facilitates the design of epitope-driven vaccines and includes capabilities for lab-based immunogenicity assays and T cell assays. Through its comprehensive analytical capabilities, EpiVax aims to enhance the development of immunotherapeutics while minimizing side effects for patients.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

EpiVax, Inc. is a biotechnology company specializing in computational immunology tools. Established in 1998 and based in Providence, Rhode Island, EpiVax focuses on developing innovative solutions to assess and mitigate immunogenic risks associated with protein therapeutics. The company offers a range of services, including interactive protein screening, immunogenicity predictions for antibody candidates, and informatics tools for evaluating host cell protein contaminants. Additionally, EpiVax provides deimmunization services to reduce immunogenicity in therapeutic proteins and develops epitope-based vaccines targeting diseases such as smallpox, tularemia, tuberculosis, and influenza. Its advanced platform also facilitates the design of epitope-driven vaccines and includes capabilities for lab-based immunogenicity assays and T cell assays. Through its comprehensive analytical capabilities, EpiVax aims to enhance the development of immunotherapeutics while minimizing side effects for patients.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

EpiVax, Inc. is a biotechnology company specializing in computational immunology tools. Established in 1998 and based in Providence, Rhode Island, EpiVax focuses on developing innovative solutions to assess and mitigate immunogenic risks associated with protein therapeutics. The company offers a range of services, including interactive protein screening, immunogenicity predictions for antibody candidates, and informatics tools for evaluating host cell protein contaminants. Additionally, EpiVax provides deimmunization services to reduce immunogenicity in therapeutic proteins and develops epitope-based vaccines targeting diseases such as smallpox, tularemia, tuberculosis, and influenza. Its advanced platform also facilitates the design of epitope-driven vaccines and includes capabilities for lab-based immunogenicity assays and T cell assays. Through its comprehensive analytical capabilities, EpiVax aims to enhance the development of immunotherapeutics while minimizing side effects for patients.

EpiVax, Inc. is a biotechnology company specializing in computational immunology tools. Established in 1998 and based in Providence, Rhode Island, EpiVax focuses on developing innovative solutions to assess and mitigate immunogenic risks associated with protein therapeutics. The company offers a range of services, including interactive protein screening, immunogenicity predictions for antibody candidates, and informatics tools for evaluating host cell protein contaminants. Additionally, EpiVax provides deimmunization services to reduce immunogenicity in therapeutic proteins and develops epitope-based vaccines targeting diseases such as smallpox, tularemia, tuberculosis, and influenza. Its advanced platform also facilitates the design of epitope-driven vaccines and includes capabilities for lab-based immunogenicity assays and T cell assays. Through its comprehensive analytical capabilities, EpiVax aims to enhance the development of immunotherapeutics while minimizing side effects for patients.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

Founded in 1993, Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on discovering, designing, and developing therapies for diseases, particularly in the areas of autoimmunity and cancer.

A Medford, Mass.-based developer of human tissue replacements.